BlackRock (LFCR holder) reports 2,010,546 Lifecore Biomedical shares in new ownership filing

Rhea-AI Filing Summary

BlackRock, Inc. reports a passive ownership position in Lifecore Biomedical, Inc. common stock. BlackRock and certain of its business units beneficially own 2,010,546 shares of Lifecore common stock, representing 5.4% of the class. Of these, 1,988,535 shares carry sole voting power, and all 2,010,546 shares are subject to BlackRock’s sole dispositive power, with no shared voting or dispositive authority. Various underlying clients and accounts have rights to dividends or sale proceeds, but no single other person has more than five percent of Lifecore’s outstanding common shares. The filing is signed by a BlackRock managing director under a power of attorney.

Key Figures

Beneficially owned shares: 2,010,546 shares Percent of class: 5.4% Sole voting power: 1,988,535 shares +3 more

6 metrics

Beneficially owned shares 2,010,546 shares Common stock of Lifecore Biomedical reported by BlackRock

Percent of class 5.4% Portion of Lifecore Biomedical common stock beneficially owned

Sole voting power 1,988,535 shares Shares for which BlackRock has sole power to vote

Shared voting power 0 shares Shares for which BlackRock has shared power to vote

Sole dispositive power 2,010,546 shares Shares for which BlackRock can solely direct disposition

Shared dispositive power 0 shares Shares with shared dispositive authority

Key Terms

beneficially owned, Sole Voting Power, dispositive power, parent holding company, +1 more

5 terms

beneficially owned financial

"reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

Sole Voting Power financial

"5 | Sole Voting Power 1,988,535.00 6 | Shared Voting Power 0.00"

Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.

dispositive power financial

"Sole power to dispose or to direct the disposition of: 2010546"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

parent holding company financial

"If a parent holding company has filed this schedule, pursuant to (ii)(G)"

Investment Company Act of 1940 regulatory

"investment company registered under the Investment Company Act of 1940"

A U.S. federal law that sets the rulebook for pooled investment vehicles such as mutual funds, exchange-traded funds and similar money managers, requiring them to register with regulators, disclose holdings and fees, limit conflicts of interest, and follow governance standards. It matters to investors because these protections and transparency rules act like a referee and scoreboard, helping people compare funds, trust that managers follow fair practices, and spot hidden costs or risks.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/29/2026 - 03:23 PM Accepted by SEC EDGAR 07/29/2026 - 03:19 PM Learn about SEC filing dates

FAQ

What percentage of Lifecore Biomedical (LFCR) does BlackRock currently own?

BlackRock and certain of its business units beneficially own 5.4% of Lifecore Biomedical’s common stock, representing 2,010,546 shares as reported in the Schedule 13G filing.

How many Lifecore Biomedical (LFCR) shares does BlackRock report voting control over?

BlackRock reports 1,988,535 shares of Lifecore Biomedical common stock with sole voting power and no shared voting power, according to the ownership disclosure.

What is BlackRock’s dispositive power over Lifecore Biomedical (LFCR) shares?

BlackRock has sole dispositive power over 2,010,546 shares of Lifecore Biomedical common stock and no shared dispositive power, meaning it alone can direct disposition of those reported shares.

Do other investors share in the economic interest of BlackRock’s Lifecore Biomedical (LFCR) holdings?

Yes. The filing states that various persons have rights to receive dividends or sale proceeds from Lifecore shares managed by BlackRock, but no individual person exceeds 5% of the total outstanding common shares.

Is BlackRock’s Lifecore Biomedical (LFCR) ownership reported on a consolidated basis?

The Schedule 13G reflects securities beneficially owned by certain BlackRock business units. It excludes holdings of other units whose ownership is disaggregated under SEC Release No. 34-39538.

Who signed the BlackRock ownership report for Lifecore Biomedical (LFCR)?

The beneficial ownership report is signed by Spencer Fleming, a Managing Director of BlackRock, Inc., acting under a Power of Attorney (Exhibit 24).

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

LIFECORE BIOMEDICAL, INC

(Name of Issuer)

Common Stock

(Title of Class of Securities)

514766104

(CUSIP Number)

06/30/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 514766104

1

Names of Reporting Persons

BlackRock, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,988,535.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,010,546.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,010,546.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: LIFECORE BIOMEDICAL, INC
(b)	Address of issuer's principal executive offices: 3515 LYMAN BOULEVARD CHASKA MN 55318
Item 2.
(a)	Name of person filing: BlackRock, Inc. In accordance with SEC Release No. 34-39538 (January 12, 1998), this Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by certain business units (collectively, the "Reporting Business Units") of BlackRock, Inc. and its subsidiaries and affiliates. It does not include securities, if any, beneficially owned by other business units whose beneficial ownership of securities are disaggregated from that of the Reporting Business Units in accordance with such release.
(b)	Address or principal business office or, if none, residence: BlackRock, Inc., 50 Hudson Yards New York, NY 10001
(c)	Citizenship: See Item 4 of Cover Page
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 514766104
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2010546
(b)	Percent of class: 5.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1988535
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 2010546
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. Various persons have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of the common stock of LIFECORE BIOMEDICAL, INC. No one person's interest in the common stock of LIFECORE BIOMEDICAL, INC is more than five percent of the total outstanding common shares.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See Exhibit 99
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BlackRock, Inc.

Signature:	Spencer Fleming
Name/Title:	Managing Director
Date:	07/29/2026

Exhibit Information

Exhibit 24: Power of Attorney Exhibit 99: Item 7